Adherium Ltd. (AU:ADR) has released an update.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Adherium Ltd. has announced a triumphant capital raise of $8.37 million, notable partnerships with health technology entities VRI and Rimidi, and its selection by AstraZeneca to incorporate Smartinhaler technology in a $1.1 million clinical trial. These strategic moves underline Adherium’s commitment to improving respiratory health outcomes and mark significant advancements in patient adherence and monitoring programs. The company’s integration of Hailie devices into health systems and its presence at the ATS International Conference further showcase its growing influence in the digital health sector.
For further insights into AU:ADR stock, check out TipRanks’ Stock Analysis page.